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AbsTrACT
Introduction The presumptive treatment of febrile illness 
with antimalarial medication is becoming less common 
in low-income and middle-income countries as access 
to reliable diagnostic tests improves. We explore whether 
the shift towards test-based antimalarial prescription, 
and the introduction of highly efficacious artemisinin 
combination therapies (ACTs), reduces critical delays in 
seeking treatment for febrile illness or increases patient 
satisfaction.
Methods We conducted countrywide repeat, cross-
sectional surveys in 118 randomly selected primary 
healthcare services in Papua New Guinea. The clinical case 
management of 1765 consecutively presenting febrile 
patients was observed and exit interviews were completed 
at discharge. This was done prior to implementation of 
test-based ACT prescription (2011) and at 12 (2012) and 
60  months (2016) postimplementation. We conducted 
multiple logistic regressions. Treatment response time was 
dichotomised as <24  hours from symptom onset vs 24+ 
hours. Satisfaction was dichotomised as a ‘high’ vs ‘low’ 
rating based on participant response to a visual, 7-point 
Likert-type scale.
results 62% (322/517) of febrile patients reported 
seeking treatment within 24  hours of symptom onset in 
2011 compared with 53% (230/434) in 2012 and 42% 
(339/814) in 2016. Adjusted ORs for reporting a treatment 
response time <24  hours in the postimplementation 
surveys were 0.77 (95% CI 0.48 to 1.26) and 0.45 (95% 
CI 0.31 to 0.65), respectively when compared with the 
preimplementation period. 53% (230/533) of febrile 
patients reported ‘high’ satisfaction with the service 
received in 2011 compared with 32% (143/449) in 2012 
and 35% (278/803) in 2016. Adjusted ORs for reporting 
high satisfaction in the postimplementation surveys were 
0.52 (95% CI 0.32 to 0.85) and 0.65 (95% CI 0.39 to 1.10), 
respectively when compared with the preimplementation 
period.
Conclusion Nationwide implementation of test-based 
ACT prescription in Papua New Guinea has increased 
the likelihood of critical treatment seeking delays and 
decreased patient satisfaction with the service received.
InTroduCTIon
A step change in malaria case management 
has recently taken place in many low-income 
and middle-income countries. The practice 
of presumptively treating all febrile patients 
with antimalarials has declined as access to 
reliable malaria rapid diagnostic tests has 
improved.1–3 In addition, older antimalarial 
regimens have been replaced with more 
effective and well tolerated artemisinin-based 
Key questions
What is already known?
 ► Health worker access to reliable malaria diagnostic 
tests and effective artemisinin combination thera-
pies (ACTs) has increased substantially in malaria 
endemic low-income and middle-income countries.
 ► The practice of presumptively treating all febrile 
patients with antimalarials has reduced markedly 
following the widespread adoption of diagnostic-test 
based ACT prescription protocols.
What are the new findings?
 ► Our results show that the introduction of diagnostic 
test-based ACT prescription in Papua New Guinea 
increased the likelihood of treatment seeking delays 
following the onset of febrile symptoms beyond the 
24 hours threshold recommended by the WHO.
 ► The increase in treatment delay may be related to 
dissatisfaction with the quality of healthcare provid-
ed to the growing proportion of febrile patients with 
a test confirmed non-malarial illness.
What do the new findings imply?
 ► The study findings suggest that improvements in the 
quality of care provided to test patients with con-
firmed malaria may still lead to a degradation in the 
perceived quality of overall febrile case manage-
ment if patients with non-malaria febrile illness do 
not receive an equivalent standard of care.
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combination treatments (ACTs).4 5 This shift towards test-
based ACT prescription represents substantial improve-
ment in the quality of care for malaria and potentially 
other febrile illnesses. For example, the introduction of 
a test-based malaria case management protocol almost 
invariably results in reduced antimalarial prescription,6–9 
implying many febrile patients previously ‘presumed’ to 
have malaria and treated accordingly are now receiving 
alternative diagnoses (and medications) based on the 
absence of detectable malaria parasitaemia.
It is not known whether the improved quality of care 
represented by the introduction of test-based ACT 
prescription has had ‘knock on’ positive effects such as 
earlier clinic presentation following the onset of febrile 
symptoms or greater patient satisfaction. These are 
important considerations. Receiving an ACT prescrip-
tion quickly, ideally within 24 hours of symptom onset, 
is critical to preventing progression from uncomplicated 
to severe malaria and possible death.5 10 Treatment delay, 
or even outright failure to seek formal treatment, are 
common in cases of suspected malaria11 12 and delays 
in treatment seeking have been attributed to dissatisfac-
tion with the quality of care available.13 14 An associated 
improvement in either treatment satisfaction or more 
responsive treatment-seeking behaviour following the 
introduction of test-based ACT prescription would, there-
fore, represent further gain on investment in malaria 
diagnostics, medications and health worker training 
beyond that obtained by the immediate benefit to the 
patients with (confirmed) malaria.
This paper explores whether the introduction of test-
based ACT prescription reduces critical delays in seeking 
treatment for febrile illness or increased patient satisfac-
tion. Drawing on data obtained during repeat, country-
wide cross-sectional surveys of randomly selected primary 
healthcare facilities in Papua New Guinea, the study eval-
uated whether patients with symptoms of febrile illness: 
(1) seek treatment earlier following implementation of a 
test-based ACT prescription protocol; (2) report greater 
satisfaction with the service received following imple-
mentation of a test-based ACT prescription protocol.
MeTHods
This paper presents data from three repeat, country-
wide, cross-sectional health facility surveys conducted 
in the years’ 2011, 2012 and 2016. The 2011 survey was 
completed when the presumptive treatment of all febrile 
patients with sulphadoxine-pyrimethamine and either 
amodiaquine or chloroquine was standard practice. 
The 2012 and 2016 surveys were completed following 
nationwide implementation of a diagnostic test-based 
ACT (artemether-lumefantrine) prescription protocol 
in late 2011. All surveys were conducted as part of a 
long-term evaluation of the Papua New Guinea National 
Malaria Control Program. A full description of the eval-
uation programme, including a detailed description of 
the health facility survey methodology, is presented else-
where.15
study setting
Papua New Guinea has a population of 7.3 million people. 
It has 22 provinces divided into four geographic regions 
(Highlands, Momase, Southern and Islands). Malaria 
is endemic in large parts of the Momase, Southern and 
Islands regions.16 Lower average temperatures prevent 
stable local transmission throughout most of the High-
lands region, although imported cases and epidemics 
occur.16 Malaria prevalence in the general population has 
reduced substantially across Papua New Guinea since a 
countrywide distribution programme of free, long-lasting 
insecticidal nets commenced in 2004.17 Most health 
services are delivered through government-providers and 
church-providers via an extensive health facility network 
with approximately 6 doctors per 100 000 population.18 
This network comprises seven levels of service provi-
sion including primary-care (levels 1–4), secondary-care 
(levels 5–6) and tertiary-care (level 7), with the structure 
and function of each level informed by National Health 
Service Standards.19 Suspected malaria accounted for 
approximately 30% of all outpatient presentations to 
primary healthcare facilities in Papua New Guinea in the 
10-year period prior to the 2011 health facility survey.20 
The Papua New Guinea National Department of Health 
implemented a test-based ACT prescription protocol in 
late 2011, replacing the former presumptive treatment 
model. The percentage of febrile patients tested for 
malaria infection subsequently rose from 17.5% to 73.5% 
between 2010 and 2016, the percentage receiving antima-
larials fell from 96.9% to 30.5%, with 100% of confirmed 
uncomplicated malaria cases receiving an ACT by 2012 
(up from 3.9% in 2010).21 The Government of Papua 
New Guinea introduced a free healthcare policy in 2014 
which, by law, should have removed all health service-re-
lated fees incurred by the patient at primary healthcare 
level; however, this was not universally implemented 
in practice.22 No other national treatment policies or 
programmes that may have significantly impacted on 
malaria or febrile case management were implemented 
during the study period nor were any significant changes 
to primary healthcare service structure, provision or 
access implemented.
study sample
A stratified sampling approach was used to select health 
facilities, with two primary healthcare facilities (n=44) 
sought from each province using a simple random 
sampling procedure. The sampling frame was a list of all 
operational primary healthcare facilities as provided by 
the Papua New Guinea National Department of Health 
(n=689). West New Britain province was intentionally 
excluded from the 2012 and 2016 surveys due to the 
disappearance of a field team within this province during 
a related, household-level malaria indicator survey in 
August 2011.23 All febrile patients meeting eligibility 
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Figure 1 The visual ‘satisfaction scale’ (from left to right ‘most’ to ‘least’ happy).
criteria attending selected health facilities during survey 
periods were recruited consecutively. The sample size, 
which took into account financial and operational 
constraints, was adequate for detecting a 20% change in 
reported treatment response times or patient satisfaction 
between survey years at a 95% level of significance with 
80% power.
survey procedure
The 2011 and 2012 surveys were carried out from June 
to November in the respective survey year, while the 2016 
survey was carried out from February to July. The shift 
in dates for the 2016 survey was the result of scheduling 
conflicts. Seasonal incidence data would suggest malaria 
transmission was highest at the time of the 2016 survey.24 
A two-to-three-member field team spent 3 days at each 
facility completing a range of survey instruments. Patients 
were considered eligible for participation if they were 
outpatients presenting with febrile symptoms, reported 
a recent history of fever and had not been treated for 
malaria infection in the past 14 days (to exclude ‘treat-
ment review’ cases). Eligible patients were identified on 
first contact with a health worker or, if circumstances 
allowed, by screening in the waiting area prior to first 
contact with a health worker. Data presented in this 
paper are derived from passive observation of clinical 
case management and structured, interviewer-adminis-
tered questionnaires completed with febrile patients at 
time of service exit. The exit questionnaire was available 
in English and Tok Pisin, the local lingua franca. Prior 
to any health facility visit, the respective provincial and 
district health authorities were informed of the study 
objectives, sites and timetable and asked to commis-
sion a health officer to accompany the field team. Oral 
informed consent was sought from the officer in charge 
at all participating health facilities and from all partic-
ipating clinicians and patients prior to clinical observa-
tion and/or interview.
Measures
Treatment seeking response time was measured by asking 
patients to estimate, to the nearest hour, the length of 
time that passed between the first sign of illness and 
arrival at the health facility. Patient satisfaction was meas-
ured by a 7-point, Likert-type scale depicting simple facial 
expressions ranging from very happy to neutral to very 
sad (figure 1). Participants were shown the scale as they 
departed the health facility and were asked to select the 
face that came closest to expressing how they felt about 
their visit today. A visual scale was preferred given an adult 
literacy rate of approximately 60%.25 The visual scale was 
adapted from an applied social research methods series26 
and extensively pilot tested with febrile patients recruited 
from non-participating primary healthcare services.
data analysis
All data were double entered into DMSys V.5.1 (Sigma Soft 
International). Stata/SE V.14.1 was used for data analysis. 
Analysis was limited to survey participants for whom both 
passive observation and exit interview data were available, 
as paired data were required for the ‘satisfaction’ anal-
yses. Participants with missing data on any of the variables 
included in the regression models (described below) were 
excluded from the respective analyses as were the small 
number of participants (n=10) who reported a travel time 
to the health facility of greater than 6 hours.
Factors potentially predictive of a prompt treatment 
response were examined by multiple logistic regres-
sion. The dependent variable was treatment response 
time as reported by participants at the time of exit inter-
view (<24 hours vs ≥24 hours). Nine independent vari-
ables were assessed for possible inclusion in the model. 
These included year of survey (2011, 2012 and 2016) as 
a measure of standard malaria case management prac-
tice (2011=presumptive, 2012=test-based ACT prescrip-
tion, 12 months postimplementation, 2016=test-based 
ACT prescription, 5 years-implementation) and eight 
potential confounding variables: participant sex (male vs 
female); participant age (<5 years, 5–15 years, 16+ years); 
geographical location of the health centre (highlands 
region vs lowlands/coastal/islands and urban vs rural); 
distance travelled to the health facility (in hours); trans-
portation cost (cost vs no cost); diagnostic test and ACT 
stock (in stock vs not in stock) and health facility fee (fee 
charged vs no fee charged). All data were obtained from 
the exit interview, with the exception of diagnostic test 
and ACT stock which was established via an audit of the 
health facility resources. Only those variables that were 
independently associated with ‘response time’ at the level 
of p<0.3 were included in the final model.
Factors potentially predictive of high treatment satis-
faction were examined by multiple logistic regression 
analysis. The dependent variable was treatment satisfac-
tion as reported by participants at the time of exit inter-
view (‘high’ satisfaction defined as a rating of A or B on 
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Table 1 Sample size by survey year and overall
Sample 2011 2012 2016 Overall
Observations 
only 
No. patients 612 439 832 1883
No. facilities 44 38 39 121
Paired 
observations/
Exit interviews
No. patients 517 434 814 1765
No. facilities 42 38 38 118
the visual scale vs ‘lower’ satisfaction defined as a rating 
of C-G). Two models were run. Survey year (2011, 2012 
and 2016) was included as a measure of standard malaria 
case management practice in both. However, to better 
understand the impact of test-based ACT prescription on 
patient satisfaction, two additional ‘practice’ indicators 
were included. Model one (binary variable, correct prac-
tice vs other) was a measure of ‘correct practice’ in accor-
dance with test-based ACT prescription protocols in which 
correct health worker practice was defined as providing 
a diagnostic test for malaria infection and either: (1) an 
ACT prescription if diagnostic test was positive; (2) or no 
antimalarial prescription if diagnostic test was negative. 
All other scenarios were defined as ‘other’. Model two 
(binary variable, correct practice vs other) was a measure 
of correct practice for malaria confirmed patients only. In 
this model, the designation of ‘correct practice’ was limited 
to those patients who received an ACT in accordance with 
test-based ACT prescription protocols. All other scenarios 
were defined as ‘other’. This distinction was made to test 
whether satisfaction is highest in the subgroup of febrile 
patients who receive a confirmation of malaria infection 
by a reliable diagnostic test and an effective antimalarial 
medication (ACT). Potential confounding variables in 
both models included: participant sex (male vs female); 
participant age (<5 years, 5–15 years, 16+ years); geograph-
ical location of the health centre (highlands region vs 
lowlands/coastal/islands and urban vs rural); distance trav-
elled to the health facility (in hours); transportation cost 
(cost vs no cost); health facility fee (fee charged vs no fee 
charged) and respondent status (ie, who provided the satis-
faction rating: patient vs caregiver of patient). All data were 
obtained from exit interview, with the exception of the two 
additional ‘correct practice’ variables which were derived 
from clinical observation. Only those variables that were 
independently associated with ‘high’ treatment satisfaction 
at the level of p<0.3 were included in the final model. All 
logistic regressions were adjusted for possible clustering at 
the health facility level using the Stata ‘cluster’ command.
resulTs
sample
Across the three survey periods, clinical observations were 
completed for a total of 1883 febrile patients collectively 
attending 121 primary healthcare facilities (table 1). 
Paired observation/interview data were available for 1765 
(94%) patients from 118 (98%) health facilities. Sample 
characteristics grouped per each of the independent and 
dependent variables included in the following regression 
analyses are presented in table 2.
Treatment seeking response time
The percentage of febrile patients attending a health 
facility and reporting a treatment delay of 24 hours or 
more increased across all three survey periods, rising from 
37.7% in 2011 to 58.3% in 2016 (table 2). The median 
treatment seeking response time (and IQR in brackets) 
by survey period was: 2011=19 hours (IQR 34), 2012=24 
hours (IQR 40), 2016=48 hours (IQR 53) and overall=24 
hours (IQR 50). Five independent variables met the 
criteria for inclusion in the multiple logistic regression, 
of which three reached statistical significance (table 3). 
Febrile patients were 23% less likely to seek treatment for 
febrile illness within 24 hours of symptom onset in the 
12-month period immediately following the implemen-
tation of test-based ACT prescription and 55% less likely 
in the period 5 years postimplementation. The odds of 
a treatment response time less than 24 hours were 51% 
lower for patients aged 16 years or older and decreased 
by 41% for every hour increase in distance to the health 
facility. A fifth independent variable, transportation cost 
also met inclusion criteria, although was not included in 
the full model as no transport cost data were collected in 
the 2011 survey. An additional multiple logistic regres-
sion analysis was run including the transport cost vari-
able, but excluding 2011 data (online supplementary 
table 1). Findings mirror those presented in table 3.
Treatment satisfaction
The percentage of febrile patients reporting a ‘high’ 
satisfaction rating decreased between the first and 
second survey periods, dropping from 43.1% in 2011 to 
31.9% in 2012, before rising to 34.6% in 2016 (table 2). 
The median treatment satisfaction rating (and IQR in 
brackets) for all survey periods and overall was 3 (IQR 
2). Five independent variables met the criteria for inclu-
sion in the first multiple logistic regression (model 1, 
table 4), of which one was statistically significant. The 
odds of reported high satisfaction were 48% lower in the 
period immediately postimplementation of test-based 
ACT prescription (2012) as compared with the period 
preimplementation (2011).
Five independent variables met the criteria for inclu-
sion in the second multiple logistic regression (model 2, 
table 4). A single statistically significant association was 
identified, with the odds of reported high satisfaction 
47% lower in the period immediately post-test and treat 
implementation (2012) as compared with the period 
preimplementation (2011).
dIsCussIon
This paper sought to examine the relationship between 
improved malaria case management practice, treatment 
seeking response times and patient satisfaction in a low-in-
come and middle-income country context. To the best of 
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Table 2 Sample characteristics by study variables*
Variable type 2011 2012 2016 Overall
Dependent variables
  Response time
  
<24 hours 322 (62.3) 230 (53.0) 339 (41.7) 891 (50.5)
24+hrs 195 (37.7) 204 (47.0) 475 (58.3) 874 (49.5)
  Satisfaction score
  
1–2 ‘high’ 230 (43.2) 143 (31.9) 278 (34.6) 651 (36.5)
3–7 ‘lower’ 303 (56.9) 306 (68.1) 525 (65.4) 1134 (63.5)
Independent variables
  Correct practice
  (model 1)
No 506 (96.0) 148 (38.3) 253 (31.2) 907 (52.6)
Yes 21 (4.0)† 238 (61.7) 559 (68.8) 818 (47.4)
  Correct practice
  (model 2)
No 535 (99.8) 323 (83.3) 658 (80.5) 1516 (87.1)
Yes 1 (0.2) 65 (16.7) 159 (19.5) 225 (12.9)
  Sex Male 254 (49.1) 236 (54.4) 429 (52.7) 919 (52.1)
Female 263 (50.9) 198 (45.6) 385 (47.3) 846 (47.9)
  Age <5 years 274 (53.0) 217 (50.0) 319 (39.2) 810 (45.9)
5–15 years 88 (17.0) 89 (20.5) 166 (20.4) 343 (19.4)
16+ years 155 (30.0) 128 (29.5) 329 (40.4) 612 (35.7)
  Respondent status Patient 191 (37.2) 124 (28.6) 336 (41.3) 651 (37.0)
Caregiver 323 (62.8) 309 (71.4) 477 (58.7) 1109 (63.0)
  Region Highlands 81 (15.7) 89 (20.5) 155 (19.0) 325 (18.4)
Other 436 (84.3) 345 (79.5) 659 (81.0) 1440 (81.6)
  Location of health facility Rural 338 (65.4) 359 (82.7) 606 (74.5) 1303 (73.8)
Urban 179 (34.6) 75 (17.3) 208 (25.5) 462 (26.2)
  Distance to health facility Hours‡ 0.5 (1.0) 0.6 (0.66) 0.5 (0.75) 0.5 (0.75)
  Transport cost Cost incurred – 140 (32.4) 222 (27.4) 362 (29.1)
No-cost incurred – 292 (67.6) 589 (72.6) 881 (70.9)
  Health facility fee Paid 308 (59.6) 235 (54.2) 356 (43.7) 899 (50.9)
Not required 209 (40.4) 199 (45.8) 458 (56.3) 866 (49.1)
  Diagnostic tests and ACT in 
stock
No 480 (92.8) 39 (9.0) 288 (35.4) 807 (45.7)
Yes 37 (7.2) 395 (91.0) 526 (64.4) 958 (54.3)
*Number (%) unless otherwise stated.
†While not widely implemented, a small number of health facilities had the necessary resources to provide test-based ACT prescription in 
2011.
‡Median (IQR).
ACT, artemisinin combination therapy.
the authors’ knowledge, this is the first study to explore 
whether the substantial investments supporting the wide-
spread implementation of test-based ACT prescription 
have had ‘knock on’ positive effects such as reducing crit-
ical delays in seeking treatment for febrile illness below 
the 24 hours threshold recommended by the WHO10 
and/or enhancing patient perception of often maligned 
primary healthcare services.
A negative and statistically significant association 
between seeking treatment for febrile illness within 24 
hours of symptom onset and implementation of test-
based ACT prescription at the primary healthcare level 
was found. Febrile patients were 23% less likely to seek 
treatment for febrile illness within 24 hours of symptom 
onset in the 12-month period immediately following 
the implementation of test-based ACT prescription and 
55% less likely in the period 5 years postimplementa-
tion. Other factors that may have influenced treatment 
seeking decision making such as transport costs, health 
facility charges and diagnostic test and ACT stocks were 
accounted for in the model and no other significant 
changes to primary healthcare provision were known to 
have been implemented during the study period.
The apparent increase in delayed (>24 hours) treat-
ment seeking for febrile illness in the 5-year period 
postimplementation of test-based ACT prescription is 
an unexpected and worrying finding. Test-based ACT 
prescription guidelines have been adopted in 96 out of 
97 countries with ongoing malaria transmission,3 yet an 
association with treatment delay has not been previously 
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Table 3 Factors associated with a treatment response of 
<24 hours
Predictor variable AOR (95% CI) P values
Survey year 2011 1.00
2012 0.77 (0.48 to 1.26) 0.31
2016 0.45 (0.31 to 0.65) <0.01
Patient age <5 years 1.00
5–15 years 0.73 (0.56 to 0.96) 0.02
16+ years 0.49 (0.38 to 0.62) <0.01
Location of health 
facility 
Highlands 1.00
Lowland/
Coastal/
Islands
1.23 (0.84 to 1.82) 0.29
Distance to health 
facility
Hours 0.59 (0.50 to 0.69) <0.01
Diagnostic tests 
and ACT in stock
No 1.00
Yes 0.86 (0.60 to 1.22) 0.39
ACT, artemisinin combination therapy; AOR, adjusted OR.
Table 4 Factors associated with a ‘high’ treatment satisfaction rating
Predictor variable 
Model 1 Model 2
AOR (95% CI) P values AOR (95% CI) P values
Correct health 
worker practice
No 1.00 1.00
Yes 1.09 (0.77 to 1.54) 0.62 1.56 (0.93 to 2.63) 0.09
Patient age <5 years 1.00 1.00
5–15 years 0.80 (0.58 to 1.09) 0.16 0.77 (0.57 to 1.05) 0.10
16+years 0.88 (0.69 to 1.12) 0.29 0.87 (0.68 to 1.12) 0.28
Location of health 
facility 
Highlands 1.00 1.00
Lowland/Coastal/Islands 0.78 (0.50 to 1.19) 0.25 0.77 (0.48 to 1.22) 0.27
Location of health 
facility 
Rural 1.00 1.00
Urban 1.18 (0.77 to 1.83) 0.45 1.24 (0.79 to 1.94) 0.35
Year of survey 2011 1.00 1.00
2012 0.52 (0.32 to 0.85) <0.01 0.53 (0.33 to 0.84) <0.01
2016 0.65 (0.39 to 1.10) 0.11 0.66 (0.41 to 1.06) 0.08
Model 1: Correct health worker practice defined as providing a diagnostic test for malaria infection and either: (1) an ACT prescription if 
diagnostic test was positive; (2) or no antimalarial prescription if diagnostic test was negative; Model 2: Correct health worker practice 
defined as prescribing an ACT in response to test-confirmed malaria infection.
ACT, artemisinin combination therapy; AOR, adjusted OR.
reported in the published literature. Findings from 
repeat cross-sectional household surveys do not indi-
cate any change in the percentage of individuals seeking 
treatment for febrile illness in Papua New Guinea over 
the past decade.27 The increased delay, therefore, does 
not appear to be a consequence of proportionately 
more or fewer febrile patients seeking assistance from 
the formal health sector. A more likely explanation may 
be the relative success of the national malaria control 
programme, which has overseen a dramatic reduction 
in general population prevalence and clinical incidence 
over the past decade.17 28 In response to this success, 
the perceived ‘threat’ of malaria infection may have 
reduced in a population already somewhat indifferent 
to the disease29 and the motivation to promptly seek 
treatment correspondingly diminished. These findings 
need to be confirmed elsewhere before more conclusive 
statements can be made in this regard, although they 
suggest greater investment in public health messaging 
encouraging prompt treatment seeking in cases of febrile 
illness may be needed in the context of declining malaria 
transmission.
The relationship between the implementation of test-
based ACT prescription and patient satisfaction was 
inconclusive. Febrile patients were 48% less likely to 
report ‘high’ satisfaction with the treatment received in 
the 12-month period immediately following implementa-
tion of the new protocol (2012) as compared with preim-
plementation (2011) and, despite some improvement, 
were still 35% less likely to do so 5 years postimplemen-
tation (2016). While it is perhaps not surprising for satis-
faction levels to drop during an initial period of change 
in health service provision (eg, due to patient expecta-
tions or health worker competency), it is concerning that 
reported satisfaction did not at least return to preimple-
mentation levels given the step change in malaria case 
management quality the transition to test-based ACT 
prescription represents. However, a somewhat different 
picture emerged when the ‘correct practice’ analysis was 
limited to confirmed malaria cases who received an ACT 
(model 2). Febrile patients with a test confirmed malaria 
infection and who received an ACT were 56% more likely 
to provide a high satisfaction rating as compared with all 
other patients. Thus, the findings suggest the implemen-
tation of test-based ACT prescription impacts patient 
satisfaction in varying ways, depending on the outcome 
of the malaria diagnostic test and the resulting treatment 
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pathway. Patients who test negative for malaria infection 
and are (correctly) not prescribed an antimalarial appear 
to be less satisfied with this outcome as compared with 
patients who test positive and receive the appropriate 
medication.
Arguably, the difference in reported satisfaction may be 
related to the subsequent diagnosis and treatment of test 
confirmed non-malaria febrile illness patients. Previous 
studies in Papua New Guinea suggest that health workers 
rarely conduct further investigations once malaria has 
been ruled out as a cause of febrile illness30 and that anti-
biotics are widely overprescribed to this patient group.31 
Coupled with the fact that diagnostic tools to assist in 
the accurate identification of fever aetiology (other than 
malaria) are scarce in resource-poor settings,32 then it is 
quite likely that many patients with non-malaria febrile 
illness, despite being appropriately managed according 
to test-based ACT prescription guidelines, may experi-
ence some degree of dissatisfaction with subsequent case 
management (which may be related to health worker 
behaviour and/or patient perceptions of the appro-
priateness of the diagnosis and treatment received). In 
other words, once malaria infection has been ruled out 
and the patient ‘exits’ the clearly defined malaria case 
management protocol and ‘enters’ a less well defined 
non-malaria febrile illness protocol, satisfaction declines. 
If substantiated, this finding raises the further possibility 
that the increasing delay in seeking treatment for febrile 
illness may be related to growing dissatisfaction with 
febrile case management at the primary healthcare level. 
Any gains in service improvement achieved through 
better quality malaria case management may, therefore, 
be offset by a perceived degradation in the treatment 
provided for other, non-malarial, febrile illnesses. This 
apparent imbalance in perceived treatment quality is 
likely to worsen as the global malaria burden continues 
to decline,3 33 unless patients with non-malaria febrile 
illness receive a standard of care equivalent to test-con-
firmed malaria cases.
The reported study was not without limitation. The 
calculation of treatment seeking response time was based 
on patient self-report which may have been subject to 
recall bias. Interviewers were trained in techniques to 
assist accurate recall to minimise this risk. The possi-
bility of self-medication or seeking treatment from an 
alternative source prior to presentation at the health 
facility was not accounted for, although recent house-
hold survey data suggest self-medication with antima-
larials is uncommon in Papua New Guinea as is seeking 
assistance from somewhere other than a health facility.27 
Treatment satisfaction was based on a single measure 
which examined patient’s satisfaction in a broad, rather 
than subject-specific, sense. However, the same measure 
was consistently used across time and there was little to 
suggest patient experience on dimensions outside of 
diagnosis, prescription and treatment counselling (eg, 
health worker attitudes, waiting times, physical environ-
ment) differed in any way between survey participants 
attending the same healthcare facility at the same time 
period. A free healthcare policy was introduced in 2014 
which should have resulted in the removal of all service 
fees at primary healthcare level, although some facilities 
included in the survey continued to charge a service fee. 
The influence of this policy could have impacted patient 
satisfaction in either direction: those who received free 
healthcare may have reported greater satisfaction while 
those who did not may have been aggrieved. In either 
case, health facility charges were accounted for in the 
regression models. Participating clinicians were aware 
that they were being observed and may have altered their 
clinical practice accordingly. The expected effect of any 
such bias would be towards perceived ‘better’ practice. 
Similarly, exit interview responses may have been subject 
to some form of social desirability bias. The 2016 survey 
was completed at a different time period as compared 
with the 2011 and 2012 surveys. Seasonal incidence data 
indicate malaria transmission would have been highest 
during the 2016 survey.24 This may have had some impact 
on rapid diagnostic test and ACT stocks, although is 
unlikely to have influenced health worker behaviour. 
Arguably, any influence on treatment seeking behaviour 
would have been towards faster treatment seeking 
response times during the higher malaria transmission 
season which was not apparent in the study findings. 
Finally, the sample excluded secondary-care and private-
sector health facilities and may not be representative of 
malaria case management in these settings.
ConClusIon
Investment in test-based ACT prescription does not 
improve treatment seeking response time or increase 
levels of treatment satisfaction among patients with 
febrile illness. Rather, the findings presented in this 
study raise the possibility that treatment seeking response 
times for febrile illness may worsen over time following 
the implementation of test-based ACT prescription due 
to dissatisfaction with the subsequent service received 
by patients with a confirmed non-malaria febrile illness. 
Test-based ACT prescription protocols should, therefore, 
be introduced alongside robust algorithms and resources 
to support the accurate identification and treatment of 
non-malarial febrile illnesses to offset these potentially 
detrimental outcomes. Greater investment in public 
health messaging encouraging prompt treatment seeking 
in cases of febrile illness may also be needed in contexts 
of declining malaria transmission. Additional research is 
needed to validate these findings and to identify and test 
appropriate solutions. In-depth qualitative studies exam-
ining community and health worker response to febrile 
illness in contexts of declining malaria transmission 
would be especially valuable.
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